一种双功能PARP-HDAC抑制剂,在尤文肉瘤中具有活性
Louise Ramos1,2,3, Sarah Truong2,3, Beibei Zhai1,2,3
1Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
概括
一种新的双功能抑制剂,kt-3283,针对PARP和HDAC酶,显示出对尤文肉瘤的增强疗效. 这种双重作用分子为治疗这种罕见的癌症提供了一个有前途的单一药物策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 基因组脱乙酶 (HDAC) 抑制可以诱导"BRCAness",一种在具有熟练的DNA修复的癌症中合成致命性的状态.
- 结合HDAC和多 (ADP-ribose) 聚合酶 (PARP) 抑制剂是对抗单剂PARP抑制剂 (PARPi) 的癌症的策略.
研究的目的:
- 报告一种具有双重PARP1/2和HDAC活性的新型双功能抑制剂kt-3283的开发和表征.
- 为了评估kt-3283在Ewing肉瘤模型中的疗效.
主要方法:
- 对PARP1/2,HDAC活性和PAR形成的测试.
- 细胞毒性,细胞周期和DNA损伤评估 (γH2AX,彗星分析).
- 使用ex vivo肺转移试验 (PuMA) 评估转移潜力.
主要成果:
- 与FDA批准的PARPi (olaparib) 和HDAC抑制剂 (vorinostat) 相比,Kt-3283在Ewing肉瘤模型中表现出更强的细胞毒性.
- 在纳米分子度下,KT-3283诱导了显著的S和G2-M细胞循环停止,并增加了DNA损伤.
- 在 ex vivo PuMA 模型中,KT-3283 抑制了 Ewing 瘤细胞殖民.
结论:
- Kt-3283为Ewing肉瘤中双PARP和HDAC抑制的临床试验提供了临床前的理由.
- 这项研究为针对尤文肉瘤的单分子双功能治疗策略提供了概念验证.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K